Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined $^{18}$F-FDG and $^{18}$F-FLT PET/CT imaging

C. Sachpekidis 1,2*, H. Goldschmidt 2,3, K. Kopka 4,5, A. Kopp-Schneider 6 and A. Dimitrakopoulou-Strauss 1

Abstract

Background: Despite the significant upgrading in recent years of the role of $^{18}$F-FDG PET/CT in multiple myeloma (MM) diagnostics, there is a still unmet need for myeloma-specific radiotracers. $^{3'}$-Deoxy-$^{3'}$-[18F]fluorothymidine ($^{18}$F-FLT) is the most studied cellular proliferation PET agent, considered a potentially new myeloma functional imaging tracer. The aim of this pilot study was to evaluate $^{18}$F-FLT PET/CT in imaging of MM patients, in the context of its combined use with $^{18}$F-FDG PET/CT.

Results: Eight patients, four suffering from symptomatic MM and four suffering from smoldering MM (SMM), were enrolled in the study. All patients underwent $^{18}$F-FDG PET/CT and $^{18}$F-FLT PET/CT imaging by means of static (whole body) and dynamic PET/CT of the lower abdomen and pelvis (dPET/CT) in two consecutive days. The evaluation of PET/CT studies was based on qualitative evaluation, semi-quantitative (SUV) calculation, and quantitative analysis based on two-tissue compartment modeling. $^{18}$F-FDG PET/CT demonstrated focal, $^{18}$F-FDG avid, MM-indicative bone marrow lesions in five patients. In contrary, $^{18}$F-FLT PET/CT showed focal, $^{18}$F-FLT avid, myeloma-indicative lesions in only two patients. In total, 48 $^{18}$F-FDG avid, focal, MM-indicative lesions were detected with $^{18}$F-FDG PET/CT, while 17 $^{18}$F-FLT avid, focal, MM-indicative lesions were detected with $^{18}$F-FLT PET/CT. The number of myeloma-indicative lesions was significantly higher for $^{18}$F-FDG PET/CT than for $^{18}$F-FLT PET/CT. A common finding was a mismatch of focally increased $^{18}$F-FDG uptake and reduced $^{18}$F-FLT uptake (lower than the surrounding bone marrow). Moreover, $^{18}$F-FLT PET/CT was characterized by high background activity in the bone marrow compartment, further complicating the evaluation of bone marrow lesions. Semi-quantitative evaluation revealed that both SUV$_{\text{mean}}$ and SUV$_{\text{max}}$ were significantly higher for $^{18}$F-FLT than for $^{18}$F-FDG in both MM lesions and reference tissue. SUV values were higher in MM lesions than in reference bone marrow for both tracers.

Conclusions: Despite the limited number of patients analyzed in this pilot study, the first results of the trial indicate that $^{18}$F-FLT does not seem suitable as a single tracer in MM diagnostics. Further studies with a larger patient population are warranted to generalize the herein presented results.

Keywords: $^{18}$F-FDG, $^{18}$F-FLT, PET/CT, Multiple myeloma

* Correspondence: christos_saxpe@yahoo.gr; c.sachpekidis@dkfz-heidelberg.de
1 Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69210 Heidelberg, Germany
2 Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
Full list of author information is available at the end of the article

© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Background

There has been an increasing interest over the past few years regarding the role of imaging in multiple myeloma (MM). This interest has been driven by the considerable technological advances, mostly in cross-sectional imaging, that have taken place and by the recent introduction of some very effective novel therapeutic agents in the oncologist's armamentarium, which have led to unparalleled levels of response in the disease. In this context, the role of molecular imaging with PET has gained significant importance in MM.

In the last years, the position of \(^{18}\)F-FDG PET/CT has been drastically upgraded in the management of MM. A number of studies have highlighted the diagnostic and prognostic value of the modality as well as its excellent performance in treatment response evaluation [1–6]. Most recently, the International Myeloma Working Group (IMWG) has recommended the use of \(^{18}\)F-FDG PET/CT as a diagnostic tool in patients with active MM, smoldering MM (SMM), and solitary plasmacytoma [7].

Although the vast majority of functional PET imaging studies is performed with \(^{18}\)F-FDG, this tracer carries some serious limitations in MM imaging: it demonstrates a false negativity incidence of approximately 11% which is associated with low hexokinase-2 expression in some MM patients, and it shows lower sensitivity than MRI in diffuse bone marrow infiltration, leading potentially to patient misclassifications if used as the only functional imaging technology [1, 8]. Moreover, \(^{18}\)F-FDG, as a glucose analog, is generally restricted in oncological imaging by both false positive (inflammation, post-surgical areas, recent use of chemotherapy, fractures, etc.) and false negative results (hyperglycemia, recent administration of high-dose steroids, etc.).

According to the previous, there is a—still unmet—need for myeloma-specific radiotracers. \(^{3'}\)-Deoxy-\(^{3'}\)-\([^{18}\)F\]fluorothymidine (\(^{18}\)F-FLT) is the most studied cellular proliferation PET agent [9]. \(^{18}\)F-FLT is taken up by cells, phosphorylated by thymidine kinase 1, which is upregulated by about tenfold during the S-phase of the cell cycle, and remains trapped intracellularly without being incorporated into DNA. Its kinetics can be described, as in the case of \(^{18}\)F-FDG, with a three-compartment model [10–12]. A recent systematic review has shown that \(^{18}\)F-FLT PET seems to be a good predictor of early response to systemic-, radio-, and concurrent chemoradiotherapy and that the modality may be developed into a tool for guiding individualization of treatment strategies [13]. Moreover, \(^{18}\)F-FLT is considered a potentially new myeloma functional imaging tracer [14].

The aim of this pilot study was to evaluate \(^{18}\)F-FLT PET/CT in imaging of MM patients, in the context of its combined use with \(^{18}\)F-FDG PET/CT.

Methods

Patients

This pilot study included eight patients (four male, four female). Four patients were suffering from symptomatic MM and four patients from SMM. Their mean age was 65.8 years (range 53–77 years). Three of the four symptomatic MM patients were suffering from primary, previously untreated myeloma, while one symptomatic MM patient had recently undergone high-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) and demonstrated nearly complete response, according to the clinical gold standard of the IMWG uniform response criteria for multiple myeloma [15]. Table 1 presents the analytical characteristics of the patients investigated. The analysis was conducted in accordance with the declaration of Helsinki with approval of the ethical committee of the University of Heidelberg and the federal office of radiation protection (BfS). The study is part of a project of a special research area (B9, SFB-TRR 79) funded by the German Research Foundation (DFG).

Data acquisition

The double-tracer study in each patient was completed in two consecutive days. For reasons of radiation protection, the patients were intravenously administered with a maximum dosage of 250 MBq \(^{18}\)F-FDG (mean = 224 MBq,

Table 1

| Patient number | Diagnosis              | Gender | Age  | \(^{18}\)F-FDG PET uptake pattern | \(^{18}\)F-FLT PET distribution |
|---------------|------------------------|--------|------|---------------------------------|-------------------------------|
| 1             | SMM                    | F      | 76   | Negative                        | Physiologic                   |
| 2             | Symptomatic MM         | M      | 68   | Focal (\(n = 3\) lesions)       | Physiologic                   |
| 3             | SMM                    | F      | 77   | Focal (\(n = 1\) lesion)        | Physiologic                   |
| 4             | SMM                    | F      | 66   | Diffuse                         | Physiologic                   |
| 5             | Symptomatic MM         | M      | 65   | Mixed (\(n = 27\) lesions)      | Pathologic (\(n = 13\) lesions) |
| 6             | Symptomatic MM         | M      | 60   | Mixed (\(n = 8\) lesions)       | Pathologic (\(n = 6\) lesions)  |
| 7             | SMM                    | F      | 61   | Focal (\(n = 9\) lesions)       | Physiologic                   |
| 8             | Symptomatic MM (pre-treated) | M  | 53   | Diffuse                         | Physiologic                   |

MM: multiple myeloma, SMM: smoldering MM, F: female, M: male
range = 168–254 MBq) on the first day and respectively a maximum dosage of 250 MBq $^{18}$F-FLT (mean = 236 MBq, range = 221–248 MBq) on the second day. Data acquisition consisted of two parts for each tracer: the dynamic part (dPET/CT studies of the lower abdomen and pelvis) and the static part (whole-body PET/CT). dPET/CT studies (field of view = 43.2 cm) were performed for 60 min using a 24-frame protocol (10 frames of 30 s, 5 frames of 60 s, 5 frames of 120 s, and 4 frames of 600 s) and a multibed protocol. The use of lower lumbar spine and pelvic entry for the dynamic series is justified by the fact that this anatomic area is regularly used for diagnostic bone marrow biopsies. After the end of the dynamic PET acquisition, the patients were asked to urinate and then additional whole-body static images from the skull to the feet were acquired with duration of 2 min per bed position for the emission scans. A dedicated PET/CT system (Biograph mCT, 128 S, Siemens Co., Erlangen, Germany) with an axial field of view of 21.6 cm with TruePoint and TrueV, operated in a three-dimensional mode, was used. A low-dose attenuation CT (120 kV, 30 mA) was used for attenuation correction of the dynamic emission PET data and for image fusion. A second low-dose CT (120 kV, 30 mA) was performed after the end of the dynamic series covering the area from the skull to the feet in order to avoid patient movement after the dynamic series. All PET images were attenuation corrected, and an image matrix of 400 × 400 pixels was used for iterative image reconstruction. Iterative image reconstruction was based on the ordered subset expectation maximization (OSEM) algorithm with six iterations and 12 subsets. The reconstructed images were converted to standardized uptake value (SUV) images based on the formula: 

$$\text{SUV} = \frac{K_r \times C_{\text{plasma}}}{C_1}$$

where $K_r$ is the input function derived from the equation $= (K_1 \times k_3)/(k_2 + k_3)$.

The accurate measurement of the input function requires arterial blood sampling. However, the input function for both tracers can be retrieved relatively simplified and noninvasively from the image data with good accuracy according to methods already reported in

![Fig. 1 Schematic representation of the three-compartment model applied for $^{18}$F-FDG and $^{18}$F-FLT. $K_1$, $k_2$, $k_3$, and $k_4$ are rate constants (1/min) and describe the directional exchanges between the three compartments ($C_{\text{plasma}}$ represents the vascular compartment, $C_1$ represents the free and non-specifically bound compartment, and $C_2$ represents the trapped compartment). $K_1$ and $k_2$ are the inflow and outflow rate constants, respectively between the plasma and the free tracer compartment, and $k_3$ and $k_4$ are the rates of phosphorylation and dephosphorylation, respectively.](image-url)
For the input function, the mean value of the VOI data from the common iliac artery, consisting of at least seven sequential ROIs, was used. The recovery coefficient was 0.85 for a diameter of 8 mm. Partial volume correction was performed for small vessels (diameter less than 8 mm) based on phantom measurements of the recovery function using dedicated software [24].

Data were statistically evaluated using the STATA/SE 12.1 (StataCorp) software on an Intel Core (2 · 3.06 GHz, 4-GB RAM) running with Mac OS X 10.8.4 (Apple Inc., Cupertino, CA, USA). The detection rate of lesions by 18F-FDG PET and by 18F-FLT PET was compared with the Yang test for clustered matched binary data using the R package clust.bin.pair. For comparison of SUV measurements for 18F-FDG PET with 18F-FLT PET in reference tissue, the reference values from the fifth lumbar vertebra and os ilium for every patient were averaged and compared by paired t test. For comparison of SUV_{mean} and SUV_{max} in 18F-FLT and 18F-FDG, only two patients were available and a patient-wise t test was performed. Note that the results cannot be transferred to the patient population. For comparison of SUV_{mean} and SUV_{max} values of both 18F-FDG PET and 18F-FLT PET between reference and lesions, mixed model analysis was performed with random intercept for the patient using lme(?) from the R package nlme. The results were considered significant for p less than 0.05 (p < 0.05).

Results
Whole-body PET/CT studies
Five patients demonstrated focal, 18F-FDG avid, MM-indicative bone marrow lesions, which correlated partially to osteolytic lesions on CT; three of these five patients demonstrated a focal 18F-FDG PET pattern, while two of them a mixed pattern. Two patients had a diffuse bone marrow tracer uptake (one of them shortly after HDT), without any 18F-FDG avid focal lesions. One patient demonstrated a negative 18F-FDG PET pattern (Table 1). In total, 48 18F-FDG avid, focal, MM-indicative lesions were detected with 18F-FDG PET/CT. The comparison between 18F-FDG PET and the underlying low-dose CT findings in these five patients revealed 18 circumscribed osteolytic lesions in CT that correlated with the 18F-FDG avid PET lesions (18/48 lesions, 37.5%). Interestingly, two patients with the initial diagnosis of SMM demonstrated focal bone marrow lesions and were classified as symptomatic MM.

18F-FLT PET/CT was characterized by high background activity in the bone marrow compartment (Fig. 2). Two patients demonstrated focal 18F-FLT avid lesions with a tracer uptake higher than that of the surrounding bone marrow (Fig. 3). In total, 17 18F-FLT avid, focal, MM-indicative lesions were detected with 18F-FLT PET/CT. All 17 18F-FLT avid lesions corresponded to respective 18F-FDG avid focal lesions including two lesions with extramedullary tumor expansion to the surrounding soft tissues after disrupting the cortical bone (Fig. 4). Moreover, two 18F-FDG-positive lymph nodes demonstrated also increased 18F-FLT uptake. Respectively, the comparison between 18F-FLT PET and the underlying low-dose CT findings in these two patients revealed 4 osteolytic lesions in CT that correlated with the 18F-FLT avid PET lesions (4/17 lesions, 23.5%). Several lesions demonstrated decreased 18F-FLT accumulation (lower than the surrounding bone marrow) in anatomical sites that corresponded to focal, 18F-FDG avid, osteolytic lesions (Fig. 5). The Yang test showed that the number of 18F-FDG avid, focal, MM-indicative lesions was significantly higher (p = 0.047) than that of 18F-FLT avid lesions. As expected, no pattern of diffuse or mixed tracer uptake (as in the case of 18F-FDG PET) could be described on 18F-FLT PET, due to the physiologically high 18F-FLT accumulation in the bone marrow.

The SUV values of the focal lesions depicted with both tracers were also calculated. For the two patients who
had lesions detectable in both modalities, patient-wise t test revealed that both $SUV_{\text{mean}}$ and $SUV_{\text{max}}$ were significantly higher for $^{18}$F-FLT than for $^{18}$F-FDG. SUV values were higher in MM lesions than in reference bone marrow for both tracers.

**Dynamic PET/CT studies**

In total, 12 $^{18}$F-FDG avid lesions and 5 $^{18}$F-FLT avid lesions were detected in the lower lumbar spine and pelvic skeleton. Due to the small number of MM-indicative focal lesions, particularly in $^{18}$F-FLT dPET/CT, no statistical comparison between MM-indicative lesions and reference bone marrow was performed regarding tracers’ kinetics. For the same reason, no comparison between the two tracers’ kinetics was performed. Time activity curves depicting tracers’ concentration in MM lesions during the 60 min of dynamic PET acquisition showed an increasing accumulation in the respective VOIs for both tracers (Fig. 6). The descriptive statistics of the kinetic $^{18}$F-FDG and $^{18}$F-FLT data are provided in the supplement (Additional file 1: Tables S1 and Additional file 2: Table S2).

**Discussion**

Functional imaging with PET provides the potential of investigating tumor biology at the molecular level after application of several radiotracers. $^{18}$F-FDG, the workhorse of PET imaging, is a surrogate of glucose utilization. The rationale of $^{18}$F-FDG application in tumor diagnostics is based on the “Warburg effect,” according to which most cancer cells rely on aerobic glycolysis to generate the energy needed for cellular processes in contrast to normal differentiated cells, which rely primarily on mitochondrial oxidative phosphorylation [25]. Nowadays, $^{18}$F-FDG PET/CT has become the mainstay for imaging evaluation of several tumor entities. In particular in the case of MM, $^{18}$F-FDG PET/CT is considered a valuable tool in the work-up of patients with the disease [7, 26]. Nevertheless, as already mentioned, $^{18}$F-FDG has some well-documented disadvantages that limit its performance in MM evaluation. Thus, the development of myeloma-specific diagnostic imaging agents that could potentially lead to personalized patient management represents a considerable need [27].

Tumor proliferation is a hallmark of the cancer phenotype and one of the useful markers for treatment response evaluation and prognosis in clinical oncology [28]. The radiolabeled thymidine analog $^{18}$F-FLT can allow noninvasive assessment of tumor proliferation [10]. $^{18}$F-FLT is incorporated into cells and undergoes phosphorylation by the enzyme thymidine kinase 1, producing $^{18}$F-FLT monophosphate ($^{18}$F-FLT-MP), which can then be sequentially phosphorylated to form $^{18}$F-FLT diphosphate ($^{18}$F-FLT-DP) and $^{18}$F-FLT triphosphate ($^{18}$F-FLT-TP); these phosphorylated products are metabolically

---

**Fig. 3** Transaxial $^{18}$F-FDG PET/CT (a) and $^{18}$F-FLT PET/CT (b) images at the pelvic level of a 65-year-old male patient with initial diagnosis of MM. Focally increased $^{18}$F-FDG accumulation (arrow, a) in the left iliac bone, reflecting an active MM lesion ($SUV_{\text{mean}} = 5.1$, $SUV_{\text{max}} = 7.2$). $^{18}$F-FLT PET/CT also demonstrates focally enhanced tracer accumulation in the same anatomical site (arrow, b), higher than the normal bone marrow uptake ($SUV_{\text{mean}} = 14.1$, $SUV_{\text{max}} = 16.8$). Notice the physiologically increased $^{18}$F-FLT bone marrow uptake rendering evaluation of skeletal lesions challenging (reference $SUV_{\text{mean}} = 6.5$, $SUV_{\text{max}} = 10.2$).

**Fig. 4** Transaxial $^{18}$F-FDG PET/CT (a) and $^{18}$F-FLT PET/CT (b) images at the thoracic level of a 60-year-old male patient with symptomatic MM. Myeloma lesion of the seventh rib with extramedullary tumor expansion to the surrounding soft tissues and thoracic vertebra after disrupting the cortical bone. The lesion shows increased accumulation in both $^{18}$F-FDG and $^{18}$F-FLT PET/CT imaging.
trapped inside cells and are not incorporated into DNA. The tracer retention within cells reflects, in part, thymidine kinase activity and is often positively correlated with cellular proliferation [29]. Although its role in everyday clinic has not been yet established, 18F-FLT PET has been studied and found to be of clinical significance in several human cancers in diagnosis and treatment response assessment [30–35].

The knowledge regarding application of 18F-FLT PET in MM is limited. Up to now, the only existing results have been published by Agool et al., who studied a group of 18 patients with different hematologic disorders, among which, two patients with MM. The authors found that the affected osteolytic areas in these two MM patients demonstrated a low 18F-FLT uptake [36]. Despite this lack in literature concerning its use in MM, 18F-FLT is considered a promising myeloma functional imaging tracer [14, 37].

The aim of this pilot study was to evaluate 18F-FLT PET/CT in imaging of MM patients, in the context of its combined use with 18F-FDG PET/CT. Our results show that, if it were used as the only functional imaging modality, 18F-FLT PET/CT would have characterized only two patients as demonstrating myeloma-associated, skeletal manifestations. In contrary, 18F-FDG PET/CT could reveal skeletal lesions in five of the included patients. Moreover, the number of myeloma-indicative lesions was significantly higher for 18F-FDG PET/CT than for 18F-FLT PET/CT. An interesting finding of our analysis, which is in line with the results published by Agool et al. [36], is that several affected osteolytic areas demonstrated a tracer mismatch of increased 18F-FDG uptake and reduced 18F-FLT uptake, indicating a phenomenon of synchronous increased glucose utilization and low proliferation rate in active myeloma lesions (Fig. 5). An explanation for this finding is the fact that MM is in general a tumor with low proliferation rate with a very small fraction of proliferating cells [38]. In agreement with this knowledge, 18F-FLT PET/CT showed increased tracer accumulation in a patient with two lesions showing extramedullary expansion to the soft tissue of the chest wall after disrupting the cortical bone (Fig. 4). Given the fact that extramedullary expansion of MM is associated with increased proliferation [39, 40], the demonstration of increased 18F-FLT uptake—not only in extramedullary but also in several medullary lesions—indicates an increased proliferation in the myeloma cells of this patient and suggests 18F-FLT PET/CT as a potential tool for highlighting the subgroup of MM patients with a hyperproliferative tumor. Unfortunately, no cytogenetic data, potentially demonstrating prognostic unfavorable abnormalities, were available in the particular patient.

Another finding of our analysis is the high background 18F-FLT activity in the bone marrow compartment, which further complicates the evaluation of bone marrow lesions in 18F-FDG PET/CT. In particular, a diffuse bone marrow infiltration would remain undetected by 18F-FLT PET/CT, as observed in our analysis, where two patients showed a diffuse pattern of 18F-FDG uptake. Although several
causes, such as recent administration of chemotherapy or granulocyte-colony stimulating factor (G-CSF) and anemia, can lead to the diffusely increased bone marrow, $^{18}$F-FDG uptake is still a finding in PET/CT imaging, which is of particular interest in the case of MM due to the nature of the disease. Nevertheless, its interpretation should be cautious; MRI remains the gold standard for assessment of the degree of bone marrow plasma cell infiltration [41].

Semi-quantitative evaluations showed that tracer uptake, reflected by SUV values, was significantly higher in myeloma-indicative lesions than in reference bone marrow for both $^{18}$F-FDG and $^{18}$F-FLT. Moreover, in these cases where lesions were detectable with both tracers (17 lesions), SUV$_{\text{mean}}$ and SUV$_{\text{max}}$ were significantly higher for $^{18}$F-FLT than for $^{18}$F-FDG.

A part of our study focused on the evaluation of the dynamic $^{18}$F-FDG and $^{18}$F-FLT PET/CT scans. As already mentioned, a three-compartment model is a reliable approach for characterization of the quantitative behavior of both tracers [11, 18–21]. Unfortunately, due to the small number of MM lesions detected in the pelvic area (particularly for $^{18}$F-FLT PET/CT), where the dynamic PET acquisition took place, no statistical evaluations regarding tracers’ kinetics were performed.

Limitations exist in this small pilot study. Firstly, the number of patients analyzed does not allow for safe conclusions to be drawn, and further studies with a larger study population are warranted to generalize the herein presented results. Nevertheless, the first results of the trial are not encouraging regarding the application of $^{18}$F-FLT PET/CT in myeloma diagnostics. Secondly, most of the PET/CT positive findings were not histopathologically confirmed. However, this is usually not possible in the clinical setting. Finally, the dynamic PET/CT studies were confined in the anatomic area of

Fig. 6 Time activity curves depicting $^{18}$F-FDG (upper row) and $^{18}$F-FLT (lower row) concentration during the 60 min of dynamic PET acquisition. The curves are derived from a MM lesion in the os ilium (curve with blue dots) and from the common iliac artery (curve with gold dots) in the respective VOIs. The curves show that both tracers accumulate increasingly in the MM lesions.
the lower abdomen and pelvis, since whole-body dynamic studies cannot be yet performed. A two-bed position protocol for the dynamic PET acquisition was used, which allows the study of a relatively large field of view of 43.2 cm. Nevertheless, new PET/CT scanners allow dynamic studies over several bed positions by using a continuous bed movement, thus facilitating the use of dynamic protocols and reducing the whole acquisition time.

Conclusions
This pilot study focusing on the combined use of 18F-FLT PET/CT and 18F-FDG PET/CT in MM showed that 18F-FLT PET/CT failed to demonstrate myeloma-associated skeletal disease in 3/5 patients with bone lesions. Moreover, the number of myeloma-indicative lesions was significantly higher for 18F-FDG PET/CT than for 18F-FLT PET/CT. Despite the limited number of patients analyzed, the first results of the trial indicate that 18F-FLT does not seem suitable as a single tracer in MM diagnostics.

Additional files

Additional file 1: Table S1. Descriptive statistics of kinetic parameters in MM lesions for the tracers 18F-FDG and 18F-FLT. The parameters $k_1$, $k_2$, $k_3$, $k_4$, and influx are expressed in 1/min. (DOCX 55 kb)

Additional file 2: Table S2. Descriptive statistics of kinetic parameters in reference bone marrow for the tracers 18F-FDG and 18F-FLT. The parameters $k_1$, $k_2$, $k_3$, $k_4$, and influx are expressed in 1/min. (DOCX 55 kb)

Acknowledgements
Not applicable.

Funding
The study was part of a special research area project (SFB TRR 79) funded by the German Research Foundation (DFG).

Availability of data and materials
Please contact the author for data requests.

Authors’ contributions
CS performed the PET/CT studies and the interpretation of scans and drafted the manuscript. HG was responsible for the selection and management of the patients included in the study. KK was responsible for the radiotracers’ production. AKS performed the statistical analysis. ADS was responsible for the combined PET/CT study design and the data evaluation, coordinated the project, and contributed to the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the ethical committee of the University of Heidelberg and the Federal Agency of Radiation Protection.

Consent for publication
All patients included gave written informed consent that their data could be used for scientific purposes.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69210 Heidelberg, Germany. 2Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany. 3National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany. 4Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany. 5German Cancer Consortium (DKTK), Heidelberg, Germany. 6Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany.

Received: 23 February 2018 Accepted: 23 March 2018
Published online: 10 April 2018

References
1. Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50–5.
2. Dimitrakopoulou-Strauss A, Hoffmann M, Bergner R, Uppenkamp M, Haberkorn U, Strauss LG. Prediction of progression-free survival in patients with multiple myeloma following anthracycline-based chemotherapy based on dynamic FDG-PET. Clin Nucl Med. 2009;34(9):576–84.
3. Bartel TB, Haessler J, Brown TL, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068–76.
4. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18F-FDG PET/CT in newly diagnosed multiple myeloma patients treated with upfront autologous transplantation. Blood. 2011;118:989–95.
5. van Lammeren-Venema D, Regelink JC, Riphagen II, Zweegman S, Hoekstra OS, Jilstra JM. 18F-fluorodeoxyglucose positron emission tomography in assessment of myeloma-related bone disease: a systematic review. Cancer. 2012;118:1971–81.
6. Zamagni E, Nanni C, Mancuso K, et al. PET/CT improves the definition of complete response and allows to detect otherwise undetectable skeletal progression in multiple myeloma. Clin Cancer Res. 2015;21:4384–90.
7. Cavo M, Terpos E, Nanni C, et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18(4):e206–17.
8. Rasche L, Angtuaco E, McDonald JE, et al. Low expression of hexokinase-2 is associated with false-negative FDG-poitron emission tomography in multiple myeloma. Blood. 2017;130(1):30–4.
9. Peck M, Pollack HA, Friesen A, et al. Applications of PET imaging with the proliferation marker [18F]FDG-PET. Q J Nucl Med Mol Imaging. 2015;59:99–104.
10. Shields AF, Griesser JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 1998;4:1334–6.
11. Shields AF, Briston DA, Chandupata S, et al. A simplified analysis of [18F]FLT deoxy-3-phosphorylmetabolism and retention. Eur J Nucl Med Mol Imaging. 2005;32:1269–75.
12. Dimitrakopoulou-Strauss A, Strauss LG. The role of 18F-FLT in cancer imaging: does it really reflect proliferation? Eur J Nucl Med Mol Imaging. 2008;35(3):523–6.
13. Bollineni VR, Kramer GM, Jansma EP, Liu Y, Oyen WJ. A systematic review on (18)F-FLT-PET uptake as a measure of treatment response in cancer patients. Eur J Cancer. 2016;65:81–97.
14. Nanni C, Zamagni E. Therapy assessment in multiple myeloma with PET. Eur J Nucl Med Mol Imaging. 2017;44(Suppl 1):111–7.
15. Durie BG, Harousseau JL, Miguel JS, International Myeloma Working Group, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
16. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991;32:623–48.
17. Sachpekidis C, Mosebach J, Freitag MT, et al. Application of (18F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: comparison of functional imaging modalities. Am J Nucl Med Mol Imaging. 2015;5:479–92.
18. Sokoloff L, Smith CB. Basic principles underlying radioisotopic methods for assay of biochemical processes in vivo. In: Greitz T, Ingvar DH, Widén L, editors. The metabolism of the human brain studied with positron emission tomography. New York: Raven Press; 1983. p. 123–48.

19. Miyazawa H, Osmon T, Petit-Taboué MC, et al. Determination of 18F-fluoro-2-deoxy-D-glucose rate constants in the anesthetized baboon brain with dynamic positron tomography. J Neurosci Methods. 1993;50:263–72.

20. Shields AF, Grierson JR, Muzik O, et al. Kinetics of 3'-deoxy-3'-[18F]-fluorothymidine uptake and retention in dogs. Mol Imaging Biol. 2002;4(1):83–9.

21. Visvikis D, Francis D, Mulligan R, et al. Comparison of methodologies for the in vivo assessment of 18FFLT utilisation in colorectal cancer. Eur J Nucl Med Mol Imaging. 2004;31(2):169–78.

22. Ohtake T, Kosaka N, Watanabe T, et al. Noninvasive method to obtain input function for measuring tissue glucose utilization of thoracic and abdominal organs. J Nucl Med. 1991;32:1432–8.

23. Germano G, Chen BC, Huang SC, Gambhir SS, Hoffman EJ, Phelps ME. Use of the abdominal aorta for arterial input function determination in hepatic and renal PET studies. J Nucl Med. 1992;33(4):613–20.

24. Burger C, Buck A. Requirements and implementations of a flexible kinetic modeling tool. J Nucl Med. 1997;38:1818–23.

25. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33.

26. Chantry A, Kazmi M, Barrington S, et al. Guidelines for the use of imaging in the management of patients with myeloma. Br J Haematol. 2017;178(3):380–93.

27. Vij R, Fowler KJ, Shokeen M. New approaches to molecular imaging of multiple myeloma. J Nucl Med. 2016;57(1):1–4.

28. Ukon N, Zhao S, Yu W, et al. Dynamic PET evaluation of elevated FLT level after sorafenib treatment in mice bearing human renal cell carcinoma xenograft. EJNMMI Res. 2016;6(1):90.

29. Lodge MA, Holdhoff M, Leal JP, et al. Repeatability of 18F-FLT PET in a multicenter study of patients with high-grade glioma. J Nucl Med. 2017;58(3):393–8.

30. Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003;44(9):1426–31.

31. Buck AK, Bommer M, Stilgenbauer S, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res. 2006;66:11055–61.

32. Yap CS, Czmin J, Fishbein MC, et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-posterior emission tomography. Chest. 2006;129:393–401.

33. Hermann K, Wieder HA, Buck AK, et al. Early response assessment using 39-deoxy-39-[18F]fluorothyymidine positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552–8.

34. Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJ, Kanders HA. 18FFLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med. 2010;51:866–74.

35. Minamimoto R, Fayad L, Advani R, et al. Diffuse large B-cell lymphoma: prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST criteria for early therapeutic monitoring. Radiology. 2016;280(1):220–9.

36. Ayool A, Slart RH, Kluin PM, de Wolf JT, Dierckx RA, Vellenga E. F-18 FLT PET: a noninvasive diagnostic tool for visualization of the bone marrow compartment in patients with aplastic anemia: a pilot study. Clin Nucl Med. 2011;36:286–9.

37. Sood A, Revansidasaila S, Kumar R. Nuclear medicine in myeloma: the state of the science and emerging trends. Hell J Nucl Med. 2011;14(1):2–5.

38. Drewinko B, Alexanian R, Boyer H, Barlogie B, Rubinow SI. The growth fraction of human myeloma cells. Blood. 1981;57(2):333–8.

39. Seshi N, Yeung J, Chang H, P53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. Leuk Res. 2009;33(10):1357–60.

40. Rasche L, Bernard C, Topp MS, et al. Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases. Ann Hematol. 2012;91(7):1031–7.

41. Zamagni E, Cavo M. The role of imaging techniques in the management of multiple myeloma. Br J Haematol. 2012;159(S):499–513.